Guided Therapeutics to place 100 cancer screening machines in Kenya

Guided Therapeutics in cooperation with its distributor, Stem World Enterprises have Submitted a Proposal to Kenya to place approximately 100 LuViva Advanced Scans at all Level 4 and 5 hospitals.

The company will be working with the Kenyan National Ministry of Health (MOH) to help achieve First Lady Margret Kenyatta’s Beyond Zero program goal of screening up to 12,000,000 Kenyan women for cervical cancer.

The plan is to screen more than 1,000,000 women in the first year, and expand the program in years two, three and four. Additionally, several counties that maintain their own hospitals would implement a complementary screening program with LuViva.

“We are pleased to have made the proposal to the Ministry of Health, Beyond Zero and the counties to bring the latest in early cervical cancer detection technology to the women of Kenya,” said Gene Cartwright, CEO and President of Guided Therapeutics. “President Kenyatta’s goal of screening fifty percent of Kenyan women annually will have a highly positive effect that will result in a significant reduction in the rate of cervical cancer.”

“This proposal is a real opportunity to bring new, impactful technology that produces an instant result, while avoiding the logistics issues that plague lab tests, so treatment can occur immediately, if necessary,” said Alphonce Omondi, CEO of Stem World. “The President’s goal and First Lady’s determination to eradicate cervical cancer is something we are pleased to be a part of and support.”

Cervical cancer is the leading cause of cancer deaths among women in Kenya, according to the MOH. According to the World Health Organization, there are 10.32 million women in Kenya at risk of developing cervical cancer.

Every year, approximately 2,454 women are diagnosed with cervical cancer and 1,676 die; the largest proportion of deaths is concentrated in Nairobi County.

It is estimated that there are 15 new cases of cervical cancer diagnosed each week in Nairobi alone. These statistics mean that an estimated 12.7 women out of every 100,000 are affected.